Posting date: October 11, 2005

This Article Reprint (PDF) HTML Version Submit a response to this article Comments: View responses Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carlson, R. J. Search for Related Content PubMed PubMed Citation Articles by Carlson, R. J. Related Collections Ethical Issues Legal/Regulatory Issues Business Of Health Minority Health Pharmaceuticals Consumer Issues Demography Related Article

Health Affairs, 10.1377/hlthaff.w5.464
Copyright © 2005 by Project HOPE

Web Exclusives

The Case Of BiDil: A Policy Commentary On Race And Genetics

¹ Rick Carlson is a clinical professor; Policy Programs, and a senior adviser in the Resource Center for Health Policy, Department of Health Services, School of Public Health, at the University of Washington in Seattle.

^*Corresponding author.

Abstract

The Food and Drug Administration (FDA) approval of BiDil unleashed a vigorous commentary, mostly critical of the decision. The FDA was soon caught between biologists, who see research and clinical utility in using racial classifications, and social scientists (and many politicians), who fear the adversities of greater discrimination. Analyses rarely addressed the practical factors the FDA had to consider in reaching a decision. Much of the literature simply assigned the question to the domain of racial politics, failing to consider the ethics of professional care, the Hippocratic oath, and the marketplace efficiency in moving drugs quickly to those who might most benefit.

Key Words: Business Of Health, Consumer Issues, Demography, Ethical Issues, Legal/Regulatory Issues, Minority Health, Pharmaceuticals

                      What's this?

Related Article

• Pamela Sankar and Jonathan Kahn
  BiDil: Race Medicine Or Race Marketing?
  Health Affairs Web Exclusive, October 11, 2005
  [Abstract] [PDF] [HTML Version]
   
  

This article has been cited by other articles:

				K. Bibbins-Domingo and A. Fernandez BiDil for Heart Failure in Black Patients: Implications of the U.S. Food and Drug Administration Approval Ann Intern Med, January 2, 2007; 146(1): 52 - 56. [Abstract] [Full Text] [PDF]

Comments: